This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Medical Practice  • Medical Ethics  • Neurology  • Alzheimer Disease  • Cognitive Disorders  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Ferris and colleagues suggest that we incorrectly assumed that he and his coauthors, Dr Kirby and Dr Thal, were "uninvolved ‘guest’ authors " and is critical that we did not contact him prior to publication of the article by Ross et al.¹ However, had we contacted Ferris for such clarification, the available evidence would have confirmed our concerns. Although Ferris, Kirby, and Thal apparently were involved with various aspects of the Merck Rofecoxib 078 study, including reportedly assisting with study design, enrolling patients, and serving on the end point adjudication committee, it appears that these individuals had limited involvement as authors responsible for the manuscript.

As Ferris et al indicate in their letter, the manuscript was drafted in August 2003 by Merck employees, and only after that were Ferris, Kirby, and Thal "approached about being coauthors on the paper." In a September 12, 2003, e-mail correspondence sent . . . [Full Text of this Article]

Catherine D. DeAngelis, MD, MPH
Editor in Chief, JAMA

Phil B. Fontanarosa, MD, MBA
Executive Deputy Editor, JAMA

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

Conflicts of Interest and Independent Data Analysis in Industry-Funded Studies—Reply
Phil B. Fontanarosa and Catherine D. DeAngelis
JAMA. 2005;294(20):2576-2577.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Kent R. Johnson and Marissa N. D. Lassere
JAMA. 2008;300(8):900.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Garret A. FitzGerald
JAMA. 2008;300(8):900-901.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Carlo Patrono
JAMA. 2008;300(8):901.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Christopher J. Hawkey
JAMA. 2008;300(8):901.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Steven Ferris, Douglas Galasko, and Louis Kirby
JAMA. 2008;300(8):901-902.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Richard Balon
JAMA. 2008;300(8):902.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Serban-Dan Costa
JAMA. 2008;300(8):902-903.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Hervé Maisonneuve
JAMA. 2008;300(8):903.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Hean T. Ong and Jin S. Cheah
JAMA. 2008;300(8):903-904.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Peter A. Lachenbruch and Ronald Wasserstein
JAMA. 2008;300(8):904.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies—Reply
Bruce M. Psaty and Richard A. Kronmal
JAMA. 2008;300(8):904.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies—Reply
Joseph S. Ross, David S. Egilman, and Harlan M. Krumholz
JAMA. 2008;300(8):904-905.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation
Joseph S. Ross, Kevin P. Hill, David S. Egilman, and Harlan M. Krumholz
JAMA. 2008;299(15):1800-1812.
ABSTRACT | FULL TEXT  

Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation
Bruce M. Psaty and Richard A. Kronmal
JAMA. 2008;299(15):1813-1817.
ABSTRACT | FULL TEXT  

Reporting Conflicts of Interest, Financial Aspects of Research, and Role of Sponsors in Funded Studies
Phil B. Fontanarosa, Annette Flanagin, and Catherine D. DeAngelis
JAMA. 2005;294(1):110-111.
EXTRACT | FULL TEXT  

Prevalence of Honorary and Ghost Authorship in Cochrane Reviews
Graham Mowatt, Liz Shirran, Jeremy M. Grimshaw, Drummond Rennie, Annette Flanagin, Veronica Yank, Graeme MacLennan, Peter C. Gøtzsche, and Lisa A. Bero
JAMA. 2002;287(21):2769-2771.
ABSTRACT | FULL TEXT  

Prevalence of Articles With Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals
Annette Flanagin, Lisa A. Carey, Phil B. Fontanarosa, Stephanie G. Phillips, Brian P. Pace, George D. Lundberg, and Drummond Rennie
JAMA. 1998;280(3):222-224.
ABSTRACT | FULL TEXT